

Target Audience

25 – 50 infectious disease and clinical microbiology specialists and trainees, gastroenterologists and clinicians taking care of patients with viral hepatitis.

Invited Faculty Members

R. Abdelmalek, Tunis, Tunisia
L. Ammari, Tunis, Tunisia
J. E. Arends, Utrecht, Netherlands
T. Asselah, Paris, France
J. Boubacar, Tunis, Tunisia
H. Dalton, Truro, United Kingdom
V. Ghisetti, Turin, Italy
N. Guha, Nottingham, United Kingdom
W. Irving, Nottingham, United Kingdom
B. Kilani, Tunis, Tunisia
H. Leblebicioglu, Samsun, Turkey
R. Ozaras, Istanbul, Turkey
M. Puoti, Milan, Italy
B. Rijnders, Rotterdam, Netherlands
D. Salmon, Paris, France
P. Sogni, Paris, France
A. Ustianowski, Manchester, United Kingdom

Contact

Contact Person (Scientific Programme)

Prof Badreddine Kilani
Department of Infectious Diseases
Rabta Hospital
University El Manar
Tunis
Tunisia

Phone +216 715 788 22
Fax +216 715 749 18
badreddine.kilani@rns.tn

Administrative Secretariat

Bahri Touil
Mice Travel
8, Rue Omar El Mokhtar
1082 Mutuelleville
Tunis
Tunisia

Phone +216 712 828 27
Fax +216 712 837 38
mice@planet.tn

Scientific picture outside: Electron micrograph of hepatitis B virus. © <http://en.wikipedia.org>




© ESCMID, September 2014



ESCMID Postgraduate Education Course

Advances in Diagnosis and Management of Viral Hepatitis

Tunis, Tunisia
6 – 7 March 2015



ESCMID Postgraduate Education Course

Advances in Diagnosis and Management of Viral Hepatitis

Organisers

- ESCMID Study Group for Viral Hepatitis (ESGVH)
- Tunisian Society of Infectious Diseases (TSID)
- Confédération Maghrébine de lutte contre les IST/SIDA (COMALISIDA)

Course Coordinators

- Joop E. Arends, Utrecht, Netherlands
- Badreddine Kilani, Tunis, Tunisia
- Dominique Salmon, Paris, France

Course Objectives

- To increase knowledge about viral hepatitis
- To review the epidemiology, prevention and outcome of viral hepatitis
- To enhance attendees' understanding of diagnosis of hepatitis
- To increase knowledge about the treatment of viral hepatitis and follow-up
- To demonstrate through case discussions all the steps of diagnosis and treatment of chronic viral hepatitis

Course Programme

Friday, 6 March 2015

09:00 Opening session

How to deal with guidelines for hepatitis C treatment

09:15 EASL and AASLD recommendations: what's new?
D. Salmon

09:45 Management of patients in resource limited settings.
H. Leblebicioglu

10:15 Current treatment options for HCV genotype 2 – 6.
M. Puoti

10:45 Coffee break

Challenges from a new era in hepatitis C treatment

11:00 HCV diagnosis and monitoring in the era of direct-acting antiviral agents.
W. Irving

11:30 Viral and host factors predictive of sustained viral response.
J. E. Arends

12:00 Epidemiology and risk factors of acute HCV.
D. Salmon

12:30 Acute HCV infection: when to treat & how to treat?
B. Rijnders

13:00 Lunch

14:30 Update on future strategies for HCV cure and eradication.
T. Asselah

Round table: case studies

15:00 Interferon free regimen in cirrhotic patients.
V. Ghisetti & A. Ustianowski

16:00 Coffee break

16:15 HCV management in people who inject drugs.
J. E. Arends

17:15 Difficult to treat patients (elderly, transplant recipients).
P. Sogni

Saturday, 7 March 2015

Special issues in hepatitis B

09:00 Hepatitis B virus: life cycle with old and new targets for antiviral therapy.
A. Ustianowski

09:30 HBV/HDV: interferon or combination with nucleoside analogs and new treatment strategies.
P. Sogni

10:00 Prophylaxis of hepatitis B and pregnancy.
L. Ammari

10:15 Update on hepatitis B vaccination.
R. Abdelmalek

10:30 Coffee break

Challenges from other hepatitis virus infections

10:45 Treatment of HBV in HIV-infected patients: opportunities and challenges.
J. E. Arends

11:15 Diagnosis and prevention of hepatitis E.
H. Dalton

11:45 HEV in immunocompromised patients.
B. Kilani

12:15 What's new in delta hepatitis?
J. Boubacar

12:45 Lunch

Round table: case studies

14:00 Non-invasive fibrosis tests: from discovery to clinical applicability.
N. Guha

14:45 Difficult to treat patients in chronic hepatitis B: do they still exist?
R. Ozaras

15:30 Coffee break

15:45 HBV therapy and iatrogenic immune suppression.
H. Leblebicioglu

16:30 Closing session

Organisation

Course Venue

Concorde les Berges du Lac Hotel
Rue du Lac Turkana
1053 Tunis
Tunisia

Phone +216 71 961 951
Fax +216 71 960 607
bergesdulac@concorde-hotels.com
www.hotelconcorde-bergesdulac.com

Registration Procedure

Register now online on the ESCMID website at www.escmid.org/education. Registration deadline is 2 February 2015.

Registration Fee

EUR 350 for ESCMID members (Full Membership/Young Scientist Membership)
EUR 400 for all others

The fee includes the scientific sessions, printed conference material, lunches and coffee breaks. Travel and accommodation are not included.

Attendance Grants

ESCMID provides a number of attendance grants for ESCMID "Young Scientist members". The grant covers the registration fee. Travel and accommodation are not included. Please apply via the ESCMID website at www.escmid.org/education before 16 January 2015. Applicants will be informed about their acceptance by 30 January 2015.

CME Accreditation

The organisers of the course will apply for European CME accreditation through EACCME.